ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1060

Therapeutic Hydroxychloroquine Blood Levels Predict Lower Mean Frequency of Recurrent Acute Care Utilization in Lupus
Abstract Number: 1061

Utilization of Electronic Health Record System to Improve Glucocorticoid Induced Osteoporosis Screening and Treatment
Abstract Number: 1062

Assessing Musculoskeletal Symptom Burden in a Cohort of Patients with Hidradenitis Suppurativa Using the IDEOM MSK-Q
Abstract Number: 1063

AI –Driven Precision in Rheumatologic Emergencies: Unveiling the Capability of Top Healthcare Chatbots
Abstract Number: 1064

Inpatient and Outpatient Palliative Care Referral Practices for Patients with Rheumatic Disease: Retrospective Chart Review at a Single Academic Medical Center
Abstract Number: 1065

A Quality Improvement Project to Improve Contraception Management in Patients with Systemic Lupus Erythematosus on Teratogenic Medications
Abstract Number: 1066

Development of a Pharmacy-Led Intervention to Improve Osteoporosis Screening in VA Community-Based Outpatient Clinics
Abstract Number: 1067

Initiation of Urate-Lowering Therapy in Patients Hospitalized with Gout Flare at a Single Center: Opportunity for Quality Improvement
Abstract Number: 1068

Improving Health Numeracy Literacy in Pediatric Patients with SLE
Abstract Number: 1069

Improving Triage Accuracy of Unclear Rheumatology Referrals: A Quality Improvement Study
Abstract Number: 1070

Evaluating & Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients
Abstract Number: 1071

Rapid Access Microscopy and Real Time Case Discussion via a Secure Messaging App Improves Diagnostic Accuracy and Management of Acute Hot Swollen Joints
Abstract Number: 1072

A 2-Year Pilot Project to Identify and Address Disparities in Health Literacy in Patients with Rheumatic Diseases Through Distribution of Surveys and Patient Education Materials
Abstract Number: 1073

Dashboard Utilization and Order Menu Revision Improve HLA-B*5801 Testing Prior to Allopurinol Initiation in High-Risk Patients in a Veteran-based Primary Care Setting
Abstract Number: 1074

Bending the Curve on Inbox Bloat: A Patient Portal Project to Mature-the-Message via Nurse Triage to Reduce Provider Inbox Time

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].